Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Shocking lung cancer: new device zaps tumors without surgery

NCT ID NCT07638228

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new device that uses electric pulses to destroy malignant lung nodules in people with early-stage lung cancer or limited lung metastases. Five participants will undergo a procedure where a needle is guided into the tumor using CT scans, then delivers electrical pulses to kill the cancer cells. The main goal is to see if the nodules are completely ablated one month after treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

5 people

The number who actually took part.

Started

Sep 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years. 2. Subjects with malignant pulmonary nodules (confirmed by histopathology) planned for ablation therapy, including: 1. Stage IA primary non-small cell lung cancer; or 2. Intrapulmonary metastatic tumors with the primary lesion well controlled. 3. Solitary lesion size ≤ 2 cm, and total number of lesions ≤ 3. 4. ECOG performance status score ≤ 2. Patients who are ineligible for surgery/radiotherapy, or who refuse surgery/radiotherapy, or who voluntarily participate. Exclusion Criteria: A patient will be excluded from participation in this clinical trial if any of the following conditions apply: 1. Severe bleeding tendency, platelet count \< 50×10⁹/L, or coagulation dysfunction (prothrombin time \> 18 s, prothrombin activity \< 40%) that cannot be corrected in the short term. 2. Anticoagulant therapy and/or antiplatelet medications discontinued for less than 1 week prior to ablation. 3. Infectious or radiation-induced inflammation around the lesion, poorly controlled skin infection at the puncture site, systemic infection, or fever \> 38.5°C. 4. Severe dysfunction of the liver, kidney, heart, lung, or brain; severe anemia, dehydration, or serious nutritional/metabolic disorders that cannot be corrected or improved in the short term. 5. Poorly controlled malignant pleural effusion. 6. Distant metastasis of lung cancer. 7. Concurrent other malignancies with extensive metastasis, and expected survival \< 6 months. 8. Presence of implanted electronic devices near the target area, or an implanted cardiac pacemaker or defibrillator. 9. The target lesion has received prior local treatments (e.g., radiotherapy, ablation) within 3 months before enrollment. 10. Participation in any drug and/or medical device clinical trial within 1 month before enrollment. 11. Pregnancy, lactation, or planned pregnancy within one year. 12. Any other condition that the investigator considers inappropriate for enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intrapulmonary metastatic tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310016, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.